PT-141 (bremelanotide) acts on melanocortin receptors in the central nervous system, the pathways associated with sexual desire and arousal.
PT-141 works centrally rather than through blood flow, engaging the neural signaling that underlies sexual motivation and response.
All PT-141 protocols are determined by licensed providers based on your evaluation and individual health profile to support safe and appropriate use.
Card is authorized after plan selection; you are not charged until a licensed provider approves your plan.
Don’t know your BMI? Calculate it here
PT-141 here refers to compounded bremelanotide, which is not FDA-approved; the only FDA-approved bremelanotide is the branded product Vyleesi. Bremelanotide is a synthetic peptide and a melanocortin receptor agonist that nonselectively activates several melanocortin receptor subtypes (MC1R through MC5R); it is thought to act centrally on melanocortin signaling rather than on blood vessels. This is a different approach from PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis), which act peripherally to increase penile blood flow. The precise mechanism by which bremelanotide influences sexual desire is not fully understood, and any use in men is off-label.
The FDA-approved product is given as a subcutaneous injection, and some compounding pharmacies prepare bremelanotide as a subcutaneous injection or as an intranasal formulation. For the approved subcutaneous product, the label directs administration at least 45 minutes before anticipated sexual activity, with no more than one dose in any 24-hour period and no more than 8 doses per month. These figures are specific to the approved injection and have not been established for compounded subcutaneous or intranasal forms, whose absorption, onset, and effects may differ. Your licensed provider will determine whether PT-141 is appropriate, along with the formulation and dose, based on your medical history, evaluation, and treatment goals.
Compounded bremelanotide is not FDA-approved. The only FDA-approved bremelanotide product is Vyleesi, a 1.75 mg single-dose subcutaneous autoinjector approved in 2019 for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Compounded bremelanotide contains the same active ingredient but is not the same as Vyleesi and is not FDA-approved for safety, effectiveness, or quality. It is dispensed only pursuant to an individual prescription written for a specific patient, and the FDA does not review compounded drugs before they are dispensed.
PT-141 is a prescription product and is initiated only after a clinical evaluation by a licensed provider who reviews your medical history, cardiovascular risk, blood pressure control, and current medications. Per the FDA-approved Vyleesi label, each dose causes a transient increase in blood pressure and a transient decrease in heart rate. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease and is not recommended for those at high cardiovascular risk, and these effects have not been studied for compounded or intranasal forms. Any use in men or for general sexual enhancement is off-label. Not all applicants qualify. Individual results vary.
PT-141 (bremelanotide) acts on melanocortin receptors in the central nervous system, primarily MC3R and MC4R, which are part of the brain pathways associated with sexual desire and arousal. Rather than affecting blood flow the way PDE5 inhibitors do, PT-141 works centrally, engaging the neural signaling that underlies sexual motivation. It is a synthetic cyclic peptide derived from the melanocortin family.
In the clinical trials supporting the FDA-approved product Vyleesi®, bremelanotide improved measures of sexual desire and reduced distress related to low desire in premenopausal women with HSDD. PT-141 also carries cardiovascular and blood-pressure-related considerations that must be evaluated against potential benefits by a licensed provider. PT-141 is not indicated for general sexual enhancement, and any use outside the FDA-approved indication is off-label and determined solely by a licensed provider.
Important Safety Information Tap to read ▾
Warning: Blood Pressure and Cardiovascular Considerations PT-141 (bremelanotide) causes a transient increase in blood pressure and a temporary decrease in heart rate following each dose. It should not be used by individuals with uncontrolled high blood pressure or known cardiovascular disease.
Do not use bremelanotide if you:
Tell your provider before starting bremelanotide if you:
Common side effects may include: nausea, flushing, headache, injection-site reactions, fatigue, and temporary changes in skin or gum pigmentation with repeated use.
Serious but less common risks may include: significant transient increases in blood pressure, and focal hyperpigmentation (darkening of areas of skin, face, or gums) with frequent or prolonged use.
This is not a complete list of side effects or contraindications. Dosing should not exceed one dose in any 24-hour period. Compounded bremelanotide is not FDA-approved. Talk to a licensed healthcare provider before starting or continuing PT-141.
0
Complete a short online wellness quiz so we can understand your goals, health history, and what’s right for you.
0
A healthcare provider reviews your information to determine if you qualify for prescription medication. No waiting rooms, no hassle.
0
If approved, your medication ships directly to your door in as little as 1–2 days; with ongoing support to keep you on track.
Every plan is reviewed by a licensed healthcare provider before medication is dispensed.
Medication arrives in discreet packaging on a consistent schedule; no pharmacy trips required.
Reach your care team with questions about dosing, side effects, or your progress; support is part of the program.
One flat rate covers your plan. No surprise fees, no insurance runaround.
PT-141 here refers to compounded bremelanotide, a synthetic peptide that acts as a melanocortin receptor agonist and is thought to act centrally on melanocortin signaling; the only FDA-approved bremelanotide product is Vyleesi. This is a different approach from PDE5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis), which act peripherally on penile blood flow, and the comparison is mechanistic only, not a claim of comparable benefit in men. PT-141 is not an FDA-approved treatment for erectile dysfunction or male sexual performance, any use in men is off-label, and the exact way bremelanotide affects sexual desire is not fully understood. Per the FDA-approved Vyleesi label, each dose can cause a transient increase in blood pressure (this has not been studied for compounded or intranasal forms), so it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease, and whether it is appropriate for you would be determined by a licensed provider.
The FDA-approved bremelanotide product is given as a subcutaneous injection, and its label directs use at least 45 minutes before anticipated sexual activity, with no more than one dose in any 24-hour period and no more than 8 doses per month. The 24-hour limit reflects, in part, a caution about additive effects on blood pressure when doses are taken close together; the monthly cap reflects cumulative-dosing concerns, including a higher risk of focal skin darkening (hyperpigmentation) with frequent use. These timing and frequency figures apply only to the FDA-approved injection and have not been established for compounded subcutaneous or intranasal forms, whose absorption, onset, and blood pressure effects may differ and should be confirmed with your prescriber.
PT-141 is not FDA-approved for men and its benefit in men has not been established, so response cannot be predicted from person to person. The figures below come only from trials of the FDA-approved product conducted in premenopausal women at the approved subcutaneous dose; they do not characterize compounded, intranasal, higher-dose, or male use and may not reflect risks in those uses. In those trials the most common side effect was nausea (about 40 percent), which required anti-nausea medication in about 13 percent of patients and led about 8 percent to stop treatment, and nausea improved for most patients with the second dose; other reported effects included flushing, injection-site reactions, headache, and vomiting. Focal skin darkening (hyperpigmentation) of the face, gums, or breasts can also occur, is more likely with frequent dosing and in people with darker skin, and may not fully resolve after stopping.
PT-141 here refers to compounded bremelanotide, which is not FDA-approved; the only FDA-approved bremelanotide product is Vyleesi, approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and it is not FDA-approved for men or for general sexual enhancement. Per the FDA-approved label, each dose causes a transient increase in blood pressure and a transient decrease in heart rate, so it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease and is not recommended for those at high cardiovascular risk. A licensed provider should confirm your blood pressure is well controlled and assess your cardiovascular risk before and during use, and these effects have not been studied for compounded or intranasal forms.
PT-141 is a prescription product, not an over-the-counter supplement, so it begins with an online assessment and a consultation with a licensed provider. The provider reviews your medical history, cardiovascular risk, blood pressure, and current medications to decide whether it is appropriate and, if so, the formulation and dose. Not all applicants qualify after evaluation, and there is no FDA-established benefit of bremelanotide in men.
